The Kirsch lab uses sophisticated genetically engineered mouse models, cellular and molecular biology, and biochemistry to study cancer and radiation biology. Our research ranges from fundamental basic questions into the mechanisms by which tumor suppressor genes prevent cancer to translational projects that focus on mechanisms of metastasis, tumor response to radiation therapy, and normal tissue injury from radiation. In a collaborative environment, we work together to make discoveries and strive to translate our research into clinical trials for patients with cancer.
David Kirsch MD, PhD is the Barbara Levine University Professor at Duke. As a physician-scientist, he cares for bone and soft tissue sarcoma patients with radiation therapy in the Duke Cancer Institute. His research program spans the continuum from basic cancer research, to translational radiation biology, to clinical trials, such as SU2C-SARC032 that is testing the combination of immunotherapy and radiation therapy for high risk extremity sarcoma. His lab research is supported by an R35 Outstanding Investigator Award from the National Cancer Institute, grants from the National Institute of Allergy and Infectious Disease and the Department of Defense, as well as several philanthropic organizations including StandUp2Cancer, the Gilbert Family Foundation, the Slifka Foundation, and the Leon Levine Foundation.